+91 789 2456 581 | info@nckpharma.com

Please sign in first

Username

Password

Lost Your Password?

Not a member?

Please simply create an account before buying/booking any courses.

Create an account for free!

Home
- About Us
NCK services
Course List
Admission Process
Knowledge Base
Contact

Home
- About Us
NCK services
Course List
Admission Process
Knowledge Base
Contact

Pharma News

Keep updating your pharma knowledge

24 Sep 2017

What are the major differences between – Breakthrough Therapy Designation Vs. Fast Track Designation Vs. Priority Review Designation Vs. Accelerated Approval

/

Posted Byadmin

/

Comments0

/

TagsAccelerated Approval, Breakthrough Therapy designation, Fast Track designation, FDA grants Priority Review for potential new indication for Brilinta, priority review, Priority Review Designation, usfda accelerated approval

Here is a quick comparison of the USFDA drug development expedited programs. This may help you to distinguishing all of them effectively.

Related Articles

Case Study: US FDA priority review grants for BMS’s sBLA for Opdivo to treat patients with resected high-risk advanced melanoma
BMS Opdivo+Yervoy combo received USFDA new indication approval.
Quick look into Roche’s Tecentriq US FDA priority review grant
USFDA approved first drug for spinal muscular atrophy
Kite Pharma’s axicabtagene got US FDA priority review status to treat NHL
USFDA approved new drug Rubraca, rucaparib

European approval for Roche’s tocilizumab for the treatment of giant cell arteritis (GCA)

USFDA approval of Verzenio to treat certain advanced/metastatic breast cancers

About Post Author

admin

Leave a Reply Cancel Reply

Search With Term

Recent Industry Update

GSK’s disinvestment of Chiron Behring to Bharat Biotech
FDA approved Cablivi (caplacizumab-yhdp) for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura
Insight on EU’s safety features of unique identifier & anti-tampering device on outer packaging require for medicines
Recordati received exclusive rights to commercialize Juxtapid in Japan from Aegerion Pharmaceuticals
Glenmark Specialty S.A’s exclusive licensing agreement with Grandpharma (China) Co. Ltd for commercializing Ryaltris in China
USFDA approved first generic of Advair Diskus
USFDA accepted the Roche’s sBLA for Tecentriq (atezolizumab) in combination with Abraxane
USFDA approved Imbruvica in combo with obinutuzumab for adult patients with previously untreated CLL/SLL
Pfizer’s launches awareness and advocacy program on antibiotic resistance
What is an “audit trail”?
US FDA approval of 0.5 ml dose of Sanofi’s Fluzone Quadrivalent in children as young as 6 months of age
Key Insights on 2018 USFDA new drug approval
Abbott to acquire medical device company, Cephea Valve Technologies
Sandoz introduces Symjepi 0.3 mg injection in US market to treat allergic reactions
US FDA accepts Roche’s sBLA for Tecentriq in combo with Abraxane and carboplatin to treat metastatic NSCLC
Aurobindo Pharma to acquire oncology products from Spectrum Pharmaceuticals in $300 mn
Bristol-Myers Squibb to acquire Celgene in deal worth $74 billion
Pfizer and GlaxoSmithKline to merge consumer healthcare units
Insight on Daiichi Sankyo’s ROS1/NTRK inhibitor DS-6051 licensing deal with AnHeart Therapeutics
Boehringer Ingelheim’s ASF COMBAT market launch: East to use Tool in prevention of African swine fever
2018 Pharma Deal: Sanofi’s agreement to buy Bioverati @ $10.9 billion
2018 Pharma Deal: Novartis’ acquisition of AveXis: $8.1 billion
US FDA approves Supernus’ sNDA to expand Oxtellar XR label
Is it always New molecule is first approved in USFDA, instead of the EU approval?
AbbVie, Pfizer’s non-exlcusive licencing agreement for biosimilar Humira
Novartis app for opium addicts gets US approval
AMAG Pharmaceuticals to Acquire Perosphere and Its Anticoagulant
Insight on USFDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor
Case Study: Pfizer’s Lyrica’s patent extension with paediatric exclusivity
What is pediatric exclusivity?

Monthly Archieves

Subscribe to NCK Newsline

Enter your email address:

Delivered by FeedBurner

Popular 1 Year Courses

KPE – C- 024 KPE’s Executive Program in Pharmaceutical Global Business
KPE-C-001 KPE’s Advance Diploma in Pharmaceutical Product Management
KPE-C-003 KPE’s Advance Diploma in Drug Regulatory Affairs
KPE-C-004 KPE’s Advance Diploma in Pharma Marketing
KPE – C- 009 KPE’s Advance Diploma in Pharmacovigilance
KPE-C-005 KPE’s Advance Diploma in Pharmaceutical Production management
KPE-C-08 KPE’s Advance Diploma in Pharmaceutical Strategic Business Management

Javascript is disabled

Javascript is disabled on your browser. Please enable it in order to use this form.

Loading

Query / Feedback

First Name

Last Name

Email Address

Your Query *

Write Here

10 plus 3 equals?*

Prove you are a human

Write here

Your form has been submitted

Thank you %NAME% for the submitting your query/feedback.

Server Side Error

We faced problems while connecting to the server or receiving data from the server. Please wait for a few seconds and try again.

If the problem persists, then check your internet connectivity. If all other sites open fine, then please contact the administrator of this website with the following information.

TextStatus: undefined
HTTP Error: undefined

Processing your request

Error

Some error has occured.

Disclaimer & Privacy Policy | Terms of Use

Copyright © 2014 - 2015 All Right Reserved - NCK Pharma Solution Private Limited

This website uses cookies to improve your learning experience. Ok Privacy Policy

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests

etc.